Evicenter
Linzess (linaclotide) in Irritable bowel syndrome with constipation
Manufacturer
AbbVie, Inc.; Ironwood Pharmaceuticals, Inc.
Prescribing information
Linzess (opens in a new tab)
Questions
19
Last updated

All questions

Clinical trials: Linzess (linaclotide) in irritable bowel syndrome with constipation

8 questions · 2 sources

Study results

How were the Linzess adult IBS-C trials designed (Trials 1 and 2)?

Applies to Irritable bowel syndrome with constipation (IBS-C) in adults

Linzess vs placebo in adult IBS-C: how many responded for 9 of 12 weeks?

Applies to Irritable bowel syndrome with constipation (IBS-C) in adults

Note: Table 3 columns are, for Trial 1 and then Trial 2, LINZESS 290 mcg once daily, placebo, and the treatment difference with its 95% CI, in that order; results are for the first 12 weeks of treatment.

Linzess vs placebo in adult IBS-C: how many responded for 6 of 12 weeks?

Applies to Irritable bowel syndrome with constipation (IBS-C) in adults

Note: Table 4 columns are, for Trial 1 and then Trial 2, LINZESS 290 mcg once daily, placebo, and the treatment difference with its 95% CI, in that order; results are for the first 12 weeks of treatment.

How soon does Linzess improve IBS-C abdominal pain and constipation in adults?

Applies to Irritable bowel syndrome with constipation (IBS-C) in adults

Does Linzess improve stool consistency and straining in adults with IBS-C?

Applies to Irritable bowel syndrome with constipation (IBS-C) in adults

Note: These results are from Trials 1 and 2 (LINZESS 290 mcg vs placebo, first 12 weeks); the label gives no figures for these endpoints.

What happens when adults with IBS-C stop Linzess (Trial 1 withdrawal)?

Applies to Irritable bowel syndrome with constipation (IBS-C) in adults

Does Linzess improve the overall abdominal score (bloating, pain, discomfort) in adult IBS-C (Trial 6)?

Applies to Irritable bowel syndrome with constipation (IBS-C) in adults

Note: Table 5 columns are LINZESS 290 mcg once daily (N=306), placebo (N=308), and the treatment difference with its 95% CI, in that order. The abdominal score is a composite of bloating, discomfort, and pain. The week 1 statement is cited on the page to the published Trial 6 report (Chang et al., Am J Gastroenterol 2021); the Prescribing Information does not report weekly results for Trial 6.

Pediatric efficacy

How effective is Linzess for IBS-C in children 7 to 17 (Trial 8)?

Applies to Irritable bowel syndrome with constipation (IBS-C) in pediatric patients 7 years of age and older

Note: Trial 8 randomized patients to LINZESS 145 mcg once daily or a higher than recommended dosage, as the first passage states. The label describes no placebo group in Trial 8; the responder rates in Table 6 are for the 145 mcg group (N=53) over 12 weeks and have no comparator, and the week 1 statement describes change from baseline.